BioAtla, Inc. (BCAB): Total Liabilities
$50.02M
As of 2025-12-31
$45.74M
As of 2026-06-30
+3.3%
3-year compound annual growth
+7.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.02M | +31.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $38.16M | -22.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $48.99M | +7.9% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $45.40M | +4.1% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $43.60M | +24.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $34.96M | n/a | 2022-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | 2025-12-31 | $50.02M | +31.1% |
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $2.23M | +19.3% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $129.8K | -89.8% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $5.10M | -58.3% |
Compare BCAB, INTS, ENTX, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗